Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens
Brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving chemotherapy and bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known which chemotherapy regimen is more effective with or without bevacizumab in treating breast cancer.

PURPOSE: This randomized phase III trial is studying six different chemotherapy regimens to compare how well they work with or without bevacizumab in treating women with stage I, stage II, or stage IIIA breast cancer that can be removed by surgery.


Options:
A: Arm Label: Avastin (bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab [Avastin] | Arm Label: Avastin (bevacizumab) + Xeloda (capecitabine); Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin], Drug: capecitabine [Xeloda] | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): Avastin (bevacizumab), Avastin (bevacizumab) + Xeloda (capecitabine) | Intervention Type: DRUG; Name: capecitabine [Xeloda]; Assigned to Arm(s): Avastin (bevacizumab) + Xeloda (capecitabine)
B: Arm Label: Arm 1A: Docetaxel then AC; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin) | Arm Label: Arm 1B Docetaxel + Bev then AC + Bev; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin) | Arm Label: Arm 2A: Docetaxel + Capecitabine then AC; Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin) | Arm Label: Arm 2B: Docetaxel + Cape + Bev then AC + Bev; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: capecitabine, Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin) | Arm Label: Arm 3A: Docetaxel + Gem then AC; Type: EXPERIMENTAL; Interventions: Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin), Drug: gemcitabine hydrochloride | Arm Label: Arm 3B: Docetaxel + Gem + Bev then AC + Bev; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin), Drug: gemcitabine hydrochloride | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm 1B Docetaxel + Bev then AC + Bev, Arm 2B: Docetaxel + Cape + Bev then AC + Bev, Arm 3B: Docetaxel + Gem + Bev then AC + Bev | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Arm 2A: Docetaxel + Capecitabine then AC, Arm 2B: Docetaxel + Cape + Bev then AC + Bev | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm 1A: Docetaxel then AC, Arm 1B Docetaxel + Bev then AC + Bev, Arm 2A: Docetaxel + Capecitabine then AC, Arm 2B: Docetaxel + Cape + Bev then AC + Bev, Arm 3A: Docetaxel + Gem then AC, Arm 3B: Docetaxel + Gem + Bev then AC + Bev | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm 1A: Docetaxel then AC, Arm 1B Docetaxel + Bev then AC + Bev, Arm 2A: Docetaxel + Capecitabine then AC, Arm 2B: Docetaxel + Cape + Bev then AC + Bev, Arm 3A: Docetaxel + Gem then AC, Arm 3B: Docetaxel + Gem + Bev then AC + Bev | Intervention Type: DRUG; Name: doxorubicin hydrochloride (Adriamycin); Assigned to Arm(s): Arm 1A: Docetaxel then AC, Arm 1B Docetaxel + Bev then AC + Bev, Arm 2A: Docetaxel + Capecitabine then AC, Arm 2B: Docetaxel + Cape + Bev then AC + Bev, Arm 3A: Docetaxel + Gem then AC, Arm 3B: Docetaxel + Gem + Bev then AC + Bev | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): Arm 3A: Docetaxel + Gem then AC, Arm 3B: Docetaxel + Gem + Bev then AC + Bev
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eribulin Mesylate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Eribulin Mesylate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: E7389 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physician's Choice | Intervention Type: DRUG; Name: E7389; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Physician's Choice; Assigned to Arm(s): 2

Answer: B